Hills Bank & Trust Co Has $1.05 Million Position in Pfizer Inc. $PFE

Hills Bank & Trust Co lowered its holdings in Pfizer Inc. (NYSE:PFE) by 39.4% during the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 42,030 shares of the biopharmaceutical company’s stock after selling 27,290 shares during the quarter. Hills Bank & Trust Co’s holdings in Pfizer were worth $1,047,000 as of its most recent filing with the SEC.

Other institutional investors and hedge funds also recently bought and sold shares of the company. Brighton Jones LLC lifted its stake in shares of Pfizer by 1,282.4% during the fourth quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after acquiring an additional 618,117 shares during the period. Revolve Wealth Partners LLC lifted its stake in shares of Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock valued at $498,000 after acquiring an additional 2,087 shares during the period. United Bank lifted its stake in shares of Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock valued at $1,408,000 after acquiring an additional 6,415 shares during the period. Sei Investments Co. lifted its stake in shares of Pfizer by 31.5% during the second quarter. Sei Investments Co. now owns 2,635,691 shares of the biopharmaceutical company’s stock valued at $63,889,000 after acquiring an additional 631,523 shares during the period. Finally, HUB Investment Partners LLC lifted its stake in shares of Pfizer by 45.3% during the second quarter. HUB Investment Partners LLC now owns 102,327 shares of the biopharmaceutical company’s stock valued at $2,480,000 after acquiring an additional 31,896 shares during the period. Institutional investors and hedge funds own 68.36% of the company’s stock.

Pfizer News Roundup

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: Pfizer announced a Europe label expansion for its hemophilia therapy Hympavzi, which could broaden the drug’s commercial opportunity and support long-term revenue growth.
• Positive Sentiment: Multiple updates highlighted ongoing clinical and development activity, including a new Korea migraine study for Nurtec ODT, a Phase 1 food-effect study for PF-07799933, a prazosin site-transfer trial, and a planned Japan RSV vaccine trial. These reinforce Pfizer’s pipeline and global expansion efforts.
• Positive Sentiment: Recent commentary around Pfizer’s Q1 earnings pointed to improving momentum in new and acquired products, especially oncology and migraine treatments, as well as progress from the Seagen integration and legal settlements that may improve clarity around future cash flow.
• Neutral Sentiment: Media coverage also noted that investor sentiment remains mixed, with some analysts and commentators arguing Pfizer still lacks strong earnings momentum and is being supported more by its dividend and defensive valuation than by a clear near-term growth catalyst.
• Negative Sentiment: Pfizer continues to face concerns about declining COVID-related sales and looming patent expirations, which have weighed on the stock even after earnings beat expectations.

Wall Street Analysts Forecast Growth

PFE has been the topic of several research reports. Zacks Research raised Pfizer from a “strong sell” rating to a “hold” rating in a research note on Tuesday, February 24th. CICC Research initiated coverage on Pfizer in a research note on Thursday, April 16th. They issued an “outperform” rating and a $33.00 target price on the stock. Morgan Stanley increased their target price on Pfizer from $27.00 to $28.00 and gave the company an “equal weight” rating in a research note on Friday, April 10th. Citigroup increased their target price on Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 29th. Finally, BMO Capital Markets reissued an “outperform” rating and issued a $30.00 target price on shares of Pfizer in a research note on Monday, March 9th. One research analyst has rated the stock with a Strong Buy rating, six have assigned a Buy rating, twelve have assigned a Hold rating and three have issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus price target of $28.84.

Pfizer Trading Down 1.7%

NYSE:PFE opened at $25.31 on Friday. Pfizer Inc. has a 1-year low of $22.45 and a 1-year high of $28.75. The business’s 50-day moving average price is $26.98 and its two-hundred day moving average price is $26.19. The company has a current ratio of 1.25, a quick ratio of 0.94 and a debt-to-equity ratio of 0.67. The firm has a market capitalization of $144.25 billion, a price-to-earnings ratio of 19.32 and a beta of 0.35.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, May 5th. The biopharmaceutical company reported $0.75 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.72 by $0.03. Pfizer had a return on equity of 19.44% and a net margin of 11.83%.The company had revenue of $14.45 billion during the quarter, compared to the consensus estimate of $13.84 billion. During the same period in the prior year, the company earned $0.92 earnings per share. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. Pfizer has set its FY 2026 guidance at 2.800-3.000 EPS. On average, equities analysts expect that Pfizer Inc. will post 2.99 earnings per share for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, June 12th. Shareholders of record on Friday, May 8th will be issued a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date is Friday, May 8th. Pfizer’s dividend payout ratio is 131.30%.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.